Abstract Body (Do not enter title and authors here): Background:

Breast cancer is the most prevalent malignancy affecting women globally and is one of the leading causes of cancer-related deaths. Cardiovascular disease (CVD) holds the highest mortality rate among women. However, the prognosis of percutaneous coronary intervention (PCI) patients with underlying breast cancer has not been well-studied.

Methods:

The National Inpatient Sample (NIS) 2017-2020 database was used to identify PCI patients with ICD-10 codes for a retrospective analysis. PCI patients were then divided into those with and without underlying breast cancer. Multivariable logistic regression was performed for composite post-PCI outcomes analyses.

Results:
Among 2,815,610 patients admitted for PCI, 3,935 had breast cancer. Patients with underlying breast cancer experienced worse post-PCI outcomes, including a higher risk of major bleeding (OR, 3.7; 95% CI, 2.9 - 4.8; P < .001) and post-PCI cardiac arrest (OR, 8.003; 95% CI, 5.39 - 11.8). The need for devices such as Impella and IABP was also higher in the breast cancer subpopulation compared to those without (OR, 6.8; 95% CI, 5.7 - 8.0) and (OR, 8.4; 95% CI, 7.44 - 9.668), respectively. Although the incidence of stroke was higher in the subpopulation, intra/post-PCI stroke was lower.
Breast cancer patients undergoing PCI showed no significant difference in hospitalization charges or length of stay.

Conclusions:
In conclusion, our study sheds light on the intricate relationship between breast cancer and percutaneous coronary intervention (PCI) outcomes. These findings underscore the importance of tailored care and close monitoring for breast cancer patients undergoing PCI.